Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.
Stephen Maxted Ansell
Research Funding - Seattle Genetics; Takeda
Anas Younes
Consultant or Advisory Role - Seattle Genetics; Takeda
Honoraria - Seattle Genetics; Takeda Pharmaceuticals International Co.
Joseph M. Connors
Research Funding - Seattle Genetics
Andrea Gallamini
No relevant relationships to disclose
Won Seog Kim
Consultant or Advisory Role - Celltrion
Jonathan W. Friedberg
Consultant or Advisory Role - Seattle Genetics
Tatyana A. Feldman
Honoraria - Seattle Genetics
Research Funding - Seattle Genetics; Takeda
Graham Collins
Consultant or Advisory Role - Takeda
Honoraria - Takeda
Nancy Bartlett
No relevant relationships to disclose
Jingyuan Wang
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Kelly Brady
Employment or Leadership Position - Takeda
Jessica Sachs
Employment or Leadership Position - Takeda
Dirk Huebner
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Naomi N. H. Hunder
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
John Radford
Consultant or Advisory Role - Takeda
Honoraria - Seattle Genetics; Takeda